Published in J Clin Oncol on April 05, 2010
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist (2011) 1.92
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Renal cell carcinoma. BMJ (2014) 1.45
Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. Mol Cell Biol (2015) 1.42
Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer (2011) 1.41
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One (2013) 1.20
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist (2011) 1.18
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One (2013) 1.17
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs (2012) 1.13
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol (2012) 1.11
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer (2012) 1.11
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08
PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J (2013) 1.07
Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biol Ther (2014) 1.06
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol (2014) 1.03
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol (2012) 1.02
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol (2012) 1.00
New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist (2011) 0.98
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study. Cancer Manag Res (2014) 0.96
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer (2014) 0.93
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag Res (2015) 0.93
Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol (2015) 0.92
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. Oncologist (2015) 0.91
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther (2012) 0.91
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res (2014) 0.91
Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc Natl Acad Sci U S A (2016) 0.90
Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol (2010) 0.90
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol (2013) 0.89
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J (2014) 0.88
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol (2013) 0.87
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience (2014) 0.87
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. Onco Targets Ther (2010) 0.87
Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol (2015) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids (2011) 0.86
Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One (2012) 0.86
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol (2015) 0.85
Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease. Cancer Res Treat (2013) 0.85
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol Med (2013) 0.84
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs (2011) 0.84
Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci (2013) 0.84
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs (2013) 0.84
From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res (2010) 0.84
Kidney cancer: overall survival is an unsuitable primary end point. Nat Rev Urol (2010) 0.84
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clin Lung Cancer (2013) 0.84
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget (2016) 0.83
Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging (2011) 0.83
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. J Geriatr Oncol (2013) 0.83
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol (2016) 0.83
Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Urol Oncol (2015) 0.82
Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma. Transl Cancer Res (2016) 0.82
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol (2015) 0.81
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol (2013) 0.81
Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World J Urol (2013) 0.81
Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol (2010) 0.81
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol (2013) 0.81
Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. Urol Oncol (2012) 0.81
Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer (2014) 0.81
A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer. Case Rep Oncol (2015) 0.80
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget (2015) 0.80
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol (2015) 0.80
Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol (2012) 0.79
Lessons learned from the bevacizumab experience. Cancer Control (2012) 0.79
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy (2015) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol (2015) 0.78
The ineligible patient: how to treat patients not included in clinical studies. World J Urol (2013) 0.78
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol (2017) 0.78
The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther (2010) 0.78
Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol (2014) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemother Pharmacol (2015) 0.78
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res (2011) 0.78
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 2.80
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol (2012) 2.48
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol (2008) 2.46
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 2.36
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol (2013) 2.29
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int (2010) 2.08
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol (2011) 2.05
Predictive parameters for internal mammary node drainage in patients with early breast cancer. Tumori (2014) 1.99
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol (2004) 1.73
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol (2014) 1.69
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol (2007) 1.68
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Treatment of liver metastases from uveal melanoma. Ann Surg Oncol (2005) 1.61
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Laparoscopic radical prostatectomy in renal transplant recipients. Urology (2009) 1.52
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer (2010) 1.47
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int (2015) 1.47
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (2011) 1.45
Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology (2009) 1.45
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology (2006) 1.45
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol (2008) 1.43
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp Urol (2010) 1.41
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2008) 1.39
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer (2010) 1.35
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol (2009) 1.34
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol (2003) 1.30
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest (2008) 1.30
EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer (2009) 1.28
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int (2011) 1.24
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev (2010) 1.16
Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer (2002) 1.14
A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. Crit Rev Oncol Hematol (2011) 1.14
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.09
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol (2008) 1.06
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol (2010) 1.03
Why don't cancer patients enter clinical trials? A review. Eur J Cancer (2006) 1.03
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep (2012) 1.03
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol (2013) 1.02
Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol (2013) 1.02
Current vaccination strategies for prostate cancer. Eur Urol (2011) 1.01
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology (2009) 1.01
Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int (2004) 1.00